Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
riluzole, Quantity: 0.5 g
Seqirus Pty Ltd
Oral Liquid, suspension
Excipient Ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; PEG-4 stearate
Oral
250 mL, 300 mL, 2 x 250 mL
(S4) Prescription Only Medicine
RILUZOLE is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Visual Identification: Slightly brown, opaque homogeneous suspension after being manually shaken; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2018-08-21
TEGLUTIK Consumer Medicine Information (CMI) Page 1 of 4 TEGLUTIK Oral Suspension Riluzole CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET READ THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet answers some common questions about TEGLUTIK oral suspension. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you using TEGLUTIK oral suspension against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT USING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT TEGLUTIK IS USED FOR The brand name of your medicine is TEGLUTIK . The active ingredient in the medicine is called riluzole, which acts on the nervous system. TEGLUTIK is used to treat people with amyotrophic lateral sclerosis (ALS), a form of MOTOR NEURONE DISEASE, which can cause muscle degeneration leading to muscle weakness. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. TEGLUTIK oral suspension is available only with a doctor's prescription. There is not enough information to recommend the use of this medicine for children under the age of 18 years. It is important to remember that you may not feel any different when you take TEGLUTIK . The benefits of using TEGLUTIK may not be noticeable to you. You should not stop taking TEGLUTIK without speaking to your doctor first. BEFORE YOU TAKE IT When you must not use it DO NOT USE TEGLUTIK IF YOU: • HAVE LIVER DISEASE • ARE PREGNANT OR INTEND TO BECOME PREGNANT • ARE BREASTFEEDING OR INTEND TO BREASTFEED DO NOT USE THIS MEDICINE IF YOU ARE ALLERGIC TO RILUZOLE OR ANY OF THE INGREDIENTS LISTED AT THE END OF THIS LEAFLET. Some of the symptoms of an allergic reaction may include: • shortness Read the complete document
Teglutik Product Information Page 1 of 16 AUSTRALIAN PRODUCT INFORMATION - TEGLUTIK ® (RILUZOLE) 1. NAME OF THE MEDICINE Riluzole 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 mL of oral suspension contains 5 mg of riluzole. Riluzole is a white to slightly yellow powder. It is very slightly soluble in water and 0.1N sodium hydroxide, sparingly soluble in 0.1N hydrochloric acid; and very soluble in methanol, acetone, acetonitrile, dichloromethane and dimethyl sulfoxide. 1 mL of oral suspension contains 400 mg of sorbitol (equivalent to 571.43 mg of sorbitol solution (70% w/w)). For the full list of excipients, see Section 6 List of excipients. 3. PHARMACEUTICAL FORM TEGLUTIK is an oral suspension containing riluzole, a benzothiazole. Chemical name: 6-(trifluoromethoxy)-2-benzothiazolamine It is a slightly brown, opaque homogenous suspension after manually shaken. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). 4.2 DOSAGE AND ADMINISTRATION DOSAGE The recommended dose is 10 mL (equivalent to 50 mg riluzole) two times a day. The maximum recommended daily dose is 100 mg (50 mg every 12 hours). No significant increase in benefit can be expected from higher daily doses. Due to the reduction in absorption observed when administered with high fat meals, riluzole should not be taken with a fat containing meal. METHOD OF ADMINISTRATION The suspension can be given per oral administration. Dilution with liquids is not necessary. The suspension is administered by means of graduated dosing syringe orally or via a Percutaneous Endoscopic Gastrostomy (PEG). Teglutik Product Information Page 2 of 16 The suspension must be manually gently shaken for at least 30 seconds by rotating the bottle by 180° and the homogeneity should be visually verified. Open the bottle, connect the dosing syringe to the bottle syringe-adapter, invert the bottle and, by maintaining the bottle in the inverted position, slowly withdraw the s Read the complete document